AzTrials
AzTrials

HypertensionNCT05671302

Walk Together: A Family-Based Intervention for Hypertension In African Americans

A study testing Walk Together in people with Hypertension and Family Relations, run by University of Texas Southwestern Medical Center at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this study is to determine the feasibility and acceptability of a novel family-based hypertension self-management intervention, Walk Together, adapted from an existing empirically-supported dyadic intervention, for implementation in primary care. Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Hypertension, Family Relations
What is being tested?
Walk Together
Could I receive a placebo?
No, everyone receives an active treatment
How many people
62 participants
Where
1 siteUnited States
Study dates
5 Apr 2024to 25 Aug 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Black or African American
  • Age 18 to 75
  • Two blood pressure values ≥ 130/ ≥ 80 in 12 months prior
  • Available family support person to join the intervention who agrees to participate
  • English-speaking

Who cannot join

  • Family support person is under the age of 18
  • Documented cognitive impairment in patient's medical record
  • Presence of severe psychiatric condition (i.e., current psychotic disorder or suicidality)
  • Participation in prior hypertension health education intervention
  • Prior participation in formative study activities (i.e., study focus groups)

Trial locations and contacts

1 site in 1 country.

United States1 site
  • UT Southwestern Family Medicine Clinic at Texas Health Dallas

    Dallas, Texas, 75231

Other trials in United States

About this study

The goal of this study is to determine the feasibility and acceptability of a novel family-based hypertension self-management intervention, Walk Together, adapted from an existing empirically-supported dyadic intervention, for implementation in primary care.

Read the detailed description

Hypertension is the driving risk factor for disparities in mortality and life expectancy between African Americans and Whites. Hypertension self-management (including blood pressure monitoring, diet, exercise, and other lifestyle changes) is critical for improving hypertension control, and prior interventions have emphasized promoting patient-level behavior change to improve self-management adherence. Though family members make substantial contributions to hypertension self-management for African Americans, family support is consistently underutilized by current hypertension self-management interventions. Family-based interventions for improving self-management are effective for other chronic conditions, including for African Americans. Evidence has demonstrated the unique and important role of family support in African Americans' hypertension management, and African Americans' preferences for the direct involvement of family in hypertension interventions. The study team will develop a family-based hypertension self-management intervention ("Walk Together") for African Americans with uncontrolled hypertension that integrates community-based participatory perspectives in the specifics of the intervention. The study team will pilot trial the culturally-adapted intervention in a primary care setting in order to examine the feasibility and acceptability of the Walk Together protocol.

Being tested
Walk Together
Keywords
Family support, Integrated health care systems, Healthy lifestyle, Community-based participatory research, African Americans
Medical subject headings
Hypertension

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Walk TogetherBehavioural

    Receive training in the use of a study-provided blood pressure cuff and hypertension education; engage in hypertension self-management goal-setting; identify barriers to self-management adherence and utilize shared problem-solving to address barriers; connect to existing clinic resources to address environmental barriers; promote relationship strengths; practice communication and behavioral skills to address relationship concerns; engage family in support of patient self-management goals.

Study groups in NCT05671302
Study groupRoleWhat they receive
Walk TogetherExperimentalWalk Together involves four sessions delivered in patients' primary care clinic over approximately two months. Sessions are dyadic (i.e., all sessions include the patient and a family support person), last 30-90 minutes, and are delivered by a trained family therapist. The intervention is a culturally-response, family-based intervention that is strengths-based and includes components of integrative behavioral couples therapy and motivational interviewing. The goals of the intervention are to (a) optimize family support and communication, (b) improve hypertension knowledge, (c) enhance self-management goal-setting, and (d) increase shared problem-solving to address self-management adherence barriers. Environmental barriers to adherence are also addressed consistent with standard care.
Receives: Behavioral: Walk Together

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Feasibility of intervention as measured by the number of participants accrued

    Feasibility of intervention is measured by the number of participants accrued or consented and ready to participate to meet the recruitment goal of 30 dyads

    Measured: 11 months

  2. Feasibility of intervention as measured by the rate of refusal among eligible patients/family members

    Feasibility of intervention is measured by the rate of refusal among eligible patients/family members which is the number of participants refusing to consent

    Measured: 11 months

  3. Adherence to the intervention as measured by the proportion of dyads successfully completing the four intervention components

    Adherence to the intervention as measured by the proportion of dyads successfully completing the four intervention components

    Measured: 11 months

  4. Adherence to the intervention as measured by the proportion of participants completing post-treatment assessments

    Adherence to the intervention as measured by the proportion of participants completing post-treatment assessment

    Measured: 11 months

  5. Attrition as measured by the proportion of consented participants who dropped out of the entire study

    Attrition is defined as measured by the proportion of consented participants who dropped out of the entire study. If the dropout rate is more than 20% then it will be considered as attrition

    Measured: 11 months

  6. Acceptability of intervention as measured by 8-item Client Satisfaction Questionnaire

    Acceptability of intervention is measured by 8-item Client Satisfaction Questionnaire. Possible scores range from 8 to 32, with higher values indicating higher satisfaction

    Measured: Protocol completion (approx. 24 months)

Secondary outcomes (12)
  1. Family relationship quality as measured by the FACES-IV Short Form at Baseline

    Family relationship quality is measured by the Family Adaptability and Cohesion Scale IV (FACES-IV) Short Form. Possible scores range from 1-5 where higher scores indicate better outcome.

    Measured: Baseline

  2. Family relationship quality as measured by the FACES-IV Short Form at following session 3

    Family relationship quality is measured by the Family Adaptability and Cohesion Scale IV (FACES-IV) Short Form. Possible scores range from 1-5 where higher scores indicate better outcome.

    Measured: Following session 3 (Feedback Session, approx. 2-3 weeks after Baseline)

  3. Family relationship quality as measured by the FACES-IV Short Form at following session 4

    Family relationship quality is measured by the Family Adaptability and Cohesion Scale IV (FACES-IV) Short Form. Possible scores range from 1-5 where higher scores indicate better outcome.

    Measured: Following session 4 (Booster Check-in session, approx. 7-8 weeks after Baseline)

  4. Family relationship quality as measured by the Chronic Illness Resources Survey at Baseline

    Family relationship quality is measured by the Chronic Illness Resources Survey. Possible scores range from 1-5 where higher scores indicate better outcome.

    Measured: Baseline

  5. Family relationship quality as measured by the Chronic Illness Resources Survey following session 3

    Family relationship quality is measured by the Chronic Illness Resources Survey. Possible scores range from 1-5 where higher scores indicate better outcome.

    Measured: Following session 3 (Feedback Session, approx. 2-3 weeks after Baseline)

  6. Family relationship quality as measured by the Chronic Illness Resources Survey following session 4

    Family relationship quality is measured by the Chronic Illness Resources Survey. Possible scores range from 1-5 where higher scores indicate better outcome.

    Measured: Following session 4 (Booster Check-in session, approx. 7-8 weeks after Baseline)

  7. Health knowledge as measured by the Hypertension (HTN) Evaluation of Lifestyle and Management Knowledge scale at Baseline

    Health knowledge is measured by the HTN Evaluation of Lifestyle and Management Knowledge scale. Possible scores range from 0-14 where higher scores indicate better health knowledge.

    Measured: Baseline

  8. Health knowledge as measured by the Hypertension (HTN) Evaluation of Lifestyle and Management Knowledge scale following session 3

    Health knowledge is measured by the HTN Evaluation of Lifestyle and Management Knowledge scale. Possible scores range from 0-14 where higher scores indicate better health knowledge.

    Measured: Following session 3 (Feedback Session, approx. 2-3 weeks after Baseline)

  9. Health knowledge as measured by the Hypertension (HTN) Evaluation of Lifestyle and Management Knowledge scale following session 4

    Health knowledge is measured by the HTN Evaluation of Lifestyle and Management Knowledge scale. Possible scores range from 0-14 where higher scores indicate better health knowledge.

    Measured: Following session 4 (Booster Check-in session, approx. 7-8 weeks after Baseline)

  10. HTN self-management as measured by the HTN Self-Care Activity Level Effects measure at Baseline

    HTN self-management is measured by the HTN Self-Care Activity Level Effects measure. The Hypertension Self-Care Activity Level Effects (H-SCALE) questionnaire assesses adherence to hypertension medication (possible subscale scores range from 0-21), physical activity engagement (possible subscale scores range from 0-14), eating a healthy diet (possible subscale scores range from 0-77), alcohol intake (possible subscale scores range from 0-1), tobacco exposure (possible subscale scores range from 0-14), and weight management (possible subscale scores range from 10-50). Possible cumulative adherence (index) scores range from 0-6 where higher scores indicate better adherence.

    Measured: Baseline

  11. HTN self-management as measured by the HTN Self-Care Activity Level Effects measure at Baseline

    HTN self-management is measured by the HTN Self-Care Activity Level Effects measure. The Hypertension Self-Care Activity Level Effects (H-SCALE) questionnaire assesses adherence to hypertension medication (possible subscale scores range from 0-21), physical activity engagement (possible subscale scores range from 0-14), eating a healthy diet (possible subscale scores range from 0-77), alcohol intake (possible subscale scores range from 0-1), tobacco exposure (possible subscale scores range from 0-14), and weight management (possible subscale scores range from 10-50). Possible cumulative adherence (index) scores range from 0-6 where higher scores indicate better adherence.

    Measured: Following session 3 (Feedback Session, approx. 2-3 weeks after Baseline)

  12. HTN self-management as measured by the HTN Self-Care Activity Level Effects measure at Baseline

    HTN self-management is measured by the HTN Self-Care Activity Level Effects measure. The Hypertension Self-Care Activity Level Effects (H-SCALE) questionnaire assesses adherence to hypertension medication (possible subscale scores range from 0-21), physical activity engagement (possible subscale scores range from 0-14), eating a healthy diet (possible subscale scores range from 0-77), alcohol intake (possible subscale scores range from 0-1), tobacco exposure (possible subscale scores range from 0-14), and weight management (possible subscale scores range from 10-50). Possible cumulative adherence (index) scores range from 0-6 where higher scores indicate better adherence.

    Measured: Following session 4 (Booster Check-in session, approx. 7-8 weeks after Baseline)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Jan 2023
  2. Study start5 Apr 2024
  3. Primary completion11 Aug 2025
  4. Study completion25 Aug 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
62 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05671302
Sponsor's protocol ID
STU-2022-0568
Other IDs
R21MD017658-01
Status last verified
Sep 2025
First submitted
13 Oct 2022
Last updated
17 Sep 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Woods SB, Hiefner AR, Udezi V, Slaughter G, Moore R, Arnold EM. 'They should walk with you': the perspectives of African Americans living with hypertension and their family members on disease self-management. Ethn Health. 2023 Apr;28(3):373-398. doi: 10.1080/13557858.2022.2040958. Epub 2022 Feb 28.

    PubMed 35227154

Questions about this trial

What is this clinical trial studying?

A study testing Walk Together in people with Hypertension and Family Relations, run by University of Texas Southwestern Medical Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Feasibility of intervention as measured by the number of participants accrued (time frame: 11 months). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05671302, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Sep 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in